65 related articles for article (PubMed ID: 38474001)
1. The increasing role of pigment epithelium-derived factor in metastasis: from biological importance to a promising target.
Abooshahab R; Al-Salami H; Dass CR
Biochem Pharmacol; 2021 Nov; 193():114787. PubMed ID: 34571004
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini-review.
Belkacemi L; Zhang SX
J Exp Clin Cancer Res; 2016 Jan; 35():4. PubMed ID: 26746675
[TBL] [Abstract][Full Text] [Related]
3. Synergy between PEDF and Doxorubicin in Breast Cancer Cells: Effects on Metastatic and Metabolic Pathways.
Abooshahab R; Al-Salami H; Dass CR
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474001
[TBL] [Abstract][Full Text] [Related]
4. Pigment epithelium-derived factor (PEDF) inhibits breast cancer metastasis by down-regulating fibronectin.
Hong H; Zhou T; Fang S; Jia M; Xu Z; Dai Z; Li C; Li S; Li L; Zhang T; Qi W; Bardeesi AS; Yang Z; Cai W; Yang X; Gao G
Breast Cancer Res Treat; 2014 Nov; 148(1):61-72. PubMed ID: 25284724
[TBL] [Abstract][Full Text] [Related]
5. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
6. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
Jan R; Huang M; Lewis-Wambi J
Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of RSK4 reverses doxorubicin resistance in human breast cancer cells via PI3K/AKT signalling pathway.
Mei Y; Liao X; Zhu L; Yang H
J Biochem; 2020 Jun; 167(6):603-611. PubMed ID: 31960922
[TBL] [Abstract][Full Text] [Related]
8. Magnoflorine improves sensitivity to doxorubicin (DOX) of breast cancer cells via inducing apoptosis and autophagy through AKT/mTOR and p38 signaling pathways.
Wei T; Xiaojun X; Peilong C
Biomed Pharmacother; 2020 Jan; 121():109139. PubMed ID: 31707337
[TBL] [Abstract][Full Text] [Related]
9. Pigment Epithelium-Derived Factor: Inhibition of Phosphorylation of Insulin Receptor (IR)/IR Substrate (IRS), Osteogeneration from Adipocytes, and Increased Levels Due to Doxorubicin Exposure.
Jones IC; Carnagarin R; Armstrong J; Lin DPL; Baxter-Holland M; Elahy M; Dass CR
Pharmaceutics; 2023 Jul; 15(7):. PubMed ID: 37514146
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics Profiling Reveals the Role of PEDF in Triple-Negative Breast Cancer Cell MDA-MB-231 under Glycaemic Loading.
Abooshahab R; Hooshmand K; Luna G; Al-Salami H; Dass CR
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839865
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity.
Kciuk M; Gielecińska A; Mujwar S; Kołat D; Kałuzińska-Kołat Ż; Celik I; Kontek R
Cells; 2023 Feb; 12(4):. PubMed ID: 36831326
[TBL] [Abstract][Full Text] [Related]
12. NFκB-Mediated Mechanisms Drive PEDF Expression and Function in Pre- and Post-Menopausal Oestrogen Levels in Breast Cancer.
Brook N; Gill J; Dharmarajan A; Chan A; Dass CR
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555293
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 mediates the effects of IGF-1R signaling in rodent bone homeostasis and fracture repair.
Esposito A; Klüppel M; Wilson BM; Meka SRK; Spagnoli A
Bone; 2023 Jan; 166():116600. PubMed ID: 36368465
[TBL] [Abstract][Full Text] [Related]
14. Current Molecular Combination Therapies Used for the Treatment of Breast Cancer.
Wang Y; Minden A
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232349
[TBL] [Abstract][Full Text] [Related]
15. The Landscape of PDK1 in Breast Cancer.
Wang N; Fu J; Li Z; Jiang N; Chen Y; Peng J
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159078
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
